



Victhom Human Bionics

Press release

For immediate release

**VICTHOM HUMAN BIONICS INC. ANNOUNCES A DELAY IN THE RELEASE OF ITS
AUDITED YEAR-END FINANCIAL STATEMENTS**

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

Quebec (Canada), April 1, 2009 – Victhom Human Bionics Inc. (“Victhom”) (TSX: VHB) announced today that its audited annual financial statements, CEO and CFO certification, management discussion and analysis (“MD&A”) and annual information form (“AIF”) for the year ended December 31, 2008 will not be released as scheduled on March 31, 2009. It is now anticipated that the release of these documents will occur no later than April 30, 2009.

In announcing the delay, Mr. Normand Rivard, Acting President and Chief Financial Officer of Victhom, indicated: “Discussions are ongoing with the objective to complete, in the short term, a transaction to allow us to continue our research and development activities. These discussions are progressing well; however, at this time, we have not achieved final agreement on such a transaction. Accordingly, this affects our ability to release our audited financial statements. Having the interest of our shareholders in mind, we have elected to delay the issuance of our annual audited financial statements and related documents until such time that we have received indications about the outcome of this possible transaction.”

Let us recall that in its last interim financial statements as of September 30, 2008, Victhom indicated that additional funding was required to fund its activities post-June 30, 2009. Since that date, Victhom had been investigating possibilities to secure the necessary funding to continue its research and development activities at their current pace given the results achieved towards bringing the Neurostep[®], a new solution for foot drop patients, to the market.

As a result of the delay, Victhom has voluntarily requested that the *Autorité des marchés financiers* and other Canadian securities regulatory authorities issue a temporary order that prohibits certain directors, officers and insiders of Victhom from trading in securities of Victhom for as long as the annual financial statements, certifications and related MD&A and AIF are not filed. The issuance of such management cease trade order does not generally affect the ability of persons who have not been directors, officers or insiders of Victhom to trade in their securities.

Victhom intends to provide information in accordance with National Policy 12-203 – Cease Trade Orders for Continuous Disclosure Defaults with respect to further developments on this matter promptly following their occurrence, including the issuance of biweekly status update reports until such time as the annual disclosure documentation is issued and filed.

Victhom intends to proceed with its annual general meeting during the month of May and expects the results for the first quarter of 2009 to be released at such time.

About Victhom

Victhom discovers, develops and manufactures bionic devices involved in the treatment of a variety of physical and physiological dysfunctions. Victhom's Neurobionix division focuses on the development and commercialization of technologies and products involving implantable devices that feature neurosensing and neurostimulation components, integrated with artificial intelligence. Victhom's Biotronix division develops biomechatronic products to support or replace peripheral limbs in what is known as the orthotics and prosthetics market.

FORWARD-LOOKING STATEMENTS

Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause Victhom's actual results, performance or achievements to be materially different from those expressed or implied by any of Victhom's statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.

- 30 -

For more information:

Victhom Human Bionics Inc.

Normand Rivard
Acting President and Chief Financial Officer
Victhom Human Bionics Inc.
Tel.: 418-872-5665
Fax: 418-864-7034
normand.rivard@victhom.com
www.victhom.com